CASE REPORT article
Front. Oncol.
Sec. Gynecological Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1555351
This article is part of the Research TopicAdvances in Diagnosis and Treatment of Endometrial CancerView all articles
Case report: A case of neuroendocrine carcinoma of the endometrium with deficient DNA mismatch repair had achieved clinical complete response after combination therapy
Provisionally accepted
- 1Zunyi Medical University, Zunyi, Guizhou Province, China
- 2Department of Oncology, Guizhou Provincial People's Hospital, Guizhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Immunotherapy has dramatically transformed the therapeutic prospect for patients with postoperative progression and metastasis. Camrelizumab, a programmed death-1 (PD-1) inhibitor, has been reported to be effective and safe for the management of advanced DNA mismatch repair deficiency (dMMR) solid tumors. Herein, we report the case of a 58-year-old female patient with neuroendocrine carcinoma of the endometrium (NECE) who was treated with camrelizumab coupled with chemotherapy, subsequent maintenance monotherapy with camrelizumab and adjuvant pelvic local radiotherapy. As of December 2024, the patient has survived for 28 months after treatment, with 26 months absence of disease progression, and is currently classified as having a clinical complete response (cCR). Our study demonstrates the combination regimen shows promising efficacy without additional adverse affects, apart from radiotherapy-related pelvic insufficiency fracture (PIF).
Keywords: Neuroendocrine carcinoma of the endometrium (NECE), DNA mismatch repair deficiency (dMMR), Programmed death-1 (PD-1) inhibitor, camrelizumab, Combination chemotherapy, adjuvant radiotherapy
Received: 04 Jan 2025; Accepted: 30 Apr 2025.
Copyright: © 2025 Xie. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Ding Xie, Zunyi Medical University, Zunyi, 563000, Guizhou Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.